Biotech Values

[iwfal]

ONTY -

It would really be odd if the SOC is just miraculously living much longer than many studies are currently showing.

Given the published enrollment curves and the rules for dealing with the halt the SOC arm has to be living longer than any previous trial.


I.e. any SOC arm with a median less than about 29 months would have been monsterously stat sig at the last interim (and would have halted regardless of the interim alpha scheme).